Wanbangde Pharmaceutical Holding Group Co Ltd - Asset Resilience Ratio
Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has an Asset Resilience Ratio of 0.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Wanbangde Pharmaceutical Holding Group Co Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Wanbangde Pharmaceutical Holding Group C to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Wanbangde Pharmaceutical Holding Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002082 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.41 Million | 0.24% |
| Total Liquid Assets | CN¥10.41 Million | 0.24% |
Asset Resilience Insights
- Limited Liquidity: Wanbangde Pharmaceutical Holding Group Co Ltd maintains only 0.24% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wanbangde Pharmaceutical Holding Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Wanbangde Pharmaceutical Holding Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Wanbangde Pharmaceutical Holding Group Co Ltd (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Wanbangde Pharmaceutical Holding Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.26% | CN¥11.15 Million ≈ $1.63 Million |
CN¥4.33 Billion ≈ $633.23 Million |
-1.74pp |
| 2014-12-31 | 2.00% | CN¥31.00 Million ≈ $4.54 Million |
CN¥1.55 Billion ≈ $226.96 Million |
+1.92pp |
| 2005-12-31 | 0.07% | CN¥491.18K ≈ $71.88K |
CN¥661.73 Million ≈ $96.83 Million |
-0.05pp |
| 2004-12-31 | 0.12% | CN¥517.57K ≈ $75.74K |
CN¥416.66 Million ≈ $60.97 Million |
-- |
About Wanbangde Pharmaceutical Holding Group Co Ltd
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascul… Read more